CMPX
Compass Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.79
close · 2026-10-30
value
40
cheaper than peers40
quality
50
stronger fundamentals50
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.85× | 86 |
| earnings yield, 3 years ago | -47.0% | 55 |
| earnings yield, 2 years ago | -42.0% | 51 |
| earnings yield, 1 year ago | -45.8% | 40 |
| cash flow yield, 1 year ago | -31.7% | 38 |
| cash flow yield, 3 years ago | -24.2% | 38 |
| cash flow yield, 2 years ago | -28.7% | 35 |
| cash flow yield, latest year | -34.7% | 35 |
| earnings yield, latest year | -53.4% | 31 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -56.7% | 55 |
| operating margin | 0.0% | 50 |
| debt to equity | 5.8% | 47 |
3 of 4 measures available
Facts
| market cap | $142M |
| free cash flow | -$31.4M |
| employees | 39 |
| first trade | 2021-04-05 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.42 | -0.36 | -0.33 | -0.37 | not reported |
| free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | not reported |
| net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | not reported |
| revenue | $0 | $850,000 | $0 | $0 | not reported |
| unusual items | not reported | not reported | $0 | $70,000 | -$50.6M |